High BMI, silicone oil tamponade, and recurrent vitreous hemorrhage predict poor visual outcomes after pars plana vitrectomy in proliferative diabetic retinopathy

Table 2 Univariate linear regression analysis of clinical parameters for final BCVA in 112 eyes from 87 PDR patients

	B (95%) CI	P
Age (years)	-0.008(-0.019-0.003)	0.162
Symptoms	-0.123(-0.256-0.011)	0.071
Duration of symptoms (months)	0.018(0.000-0.035)	0.049
Course of diabetes (years)	-0.016(-0.035-0.003)	0.103
Diabetes treatment	-0.007(-0.165-0.150)	0.929
BMI (kg/m²)	0.044(0.010–0.078)	0.012
Hypertension	0.097(-0.171-0.365)	0.477
Cerebral and myocardial infarction	0.025(-0.302-0.353)	0.878
Staging of DR	0.225(0.071–0.380)	0.005
Tamponade	0.380(0.117–0.642)	0.005
Recurrent VH	0.625(0.333–0.917)	< 0.001
Final IOP (mmHg)	0.061(0.026–0.096)	0.001
GLU (mmol/L)	0.040(-0.025-0.106)	0.225
HbA1c (%)	0.005(-0.073-0.084)	0.890

PDR, proliferative diabetic retinopathy; BMI, body mass index; DR, diabetic retinopathy; BCVA, best-corrected visual acuity; log MAR, logarithm of minimum angle of resolution; VH, vitreous hemorrhage; IOP, intraocular pressure; GLU, glucose; HbA1c, hemoglobin A1c; B, regression coefficient; CI, confidence interval
The staging of DR in this study was determined based on the definitions provided in the 2014 Chinese Clinical Guidelines for the Diagnosis and Treatment of DR [12]

ISSN: 1471-2415